Bellevue Group AG
Q2 2020 13F-HR Holdings
Net value change ($000)
+1,909,316
(37.0%)
New positions
17
Sold out positions
23
Turnover %
2.3%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q1 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ESPR | 113,260 | 71.3% |
| NBIX | 109,623 | 38.9% |
| MGNX | 104,045 | 292.1% |
| INCY | 98,915 | 40.6% |
| MRNA | 96,471 | 81.5% |
| IONS | 90,224 | 22.8% |
| ARGX | 86,502 | 67.4% |
| AGIO | 76,616 | 55.3% |
| Myovant Sciences Ltd. | 59,467 | 163.6% |
| MyoKardia, Inc. | 55,254 | 89.9% |
Top Reduces (Value $000, Stocks/ETFs)
| AKCEA THERAPEUTICS, INC. | -25,788 | -56.3% |
| ISRG | -20,104 | -18.4% |
| ILMN | -18,777 | -34.5% |
| VRTX | -17,674 | -5.8% |
| QUIDEL CORP /DE/ | -11,146 | -100.0% |
| INTERCEPT PHARMACEUTICALS, INC. | -10,863 | -24.3% |
| SUPN | -9,945 | -100.0% |
| ALGN | -8,191 | -23.2% |
| JAZZ | -4,913 | -13.3% |
| QGEN | -3,852 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|